Revenue Rallies QoQ,Overseas Products Likely to Drive Growth
发布时间:2026-05-11 来源:华泰证券
Sanqi Interactive has reported 1Q26 revenue/attributable net profit (NP)/recurring attributable NP of RMB3,720/873/610mn (-12.3/+59.0/+13.7% YoY, +6.2/+57.3/ +4.3% QoQ). Profitability improved significantly with contributions from new titles. We are optimistic about the competitiveness of the company's overseas products, represented by the SLG title, Last Asylum: Plague, and the new product cycle. BUY.
Revenue rebounds QoQ; new titles perform strongly
1Q26 revenue rebounded QoQ, driven by incremental contributions from newly launched titles and the continued refinement of the operations of existing games. On the product side, new releases such as Survive for 33 Days, RO Ragnarok: World Tour, and Last Asylum: Plague performed well, boosting quarterly revenue. Overseas SLG title Last Asylum: Plague stood out, ranking among the top-ten globally in Sensor Tower's March 2026 revenue growth list, demonstrating the company's sustained competitiveness in the SLG segment. Existing titles such as Puzzles & Survival and Douluo Continent: Soul Master Duel maintained stable contributions, with version updates and refined operations improving user retention and monetization. We believe the company has entered a new product cycle, where a mix of new and existing titles is likely to drive a gradual revenue recovery.
Investment gains boost profit; expense ratios increase
Attributable NP in 1Q26 rose by 59.0% YoY, far exceeding revenue growth, mainly due to fair value gains from the IPO of associate, Knowledge Atlas Technology, which drove investment income up by 981.35% YoY to RMB359mn, materially enhancing profitability. Additionally, the company has invested directly or indirectly in multiple innovative firms including Knowledge Atlas Technology, Moonshot AI, Baichuan AI, AIsphere, and BrainCo. 1Q26 recurring attributable NP grew by 13.7% YoY, reflecting steady improvement in core gaming profitability. The sales/R&D/administrative expense ratio was 50.5/5.1/3.7% (+6.0/+0.1/ +0.1pp QoQ). We believe the higher sales expense ratio stemmed primarily from increased user acquisition spending for the new game, Last Asylum: Plague.
Robust product pipeline supports future earnings growth
The company continues advancing its SLG+X global strategy, with a rich product pipeline. It has 11 self-developed and 16 licensed titles, covering multiple genres including SLG and RPG, each with over ten titles. Soul Land: Legacy and Fights Break Spheres: Dou Di Zhi Lu leverage established IPs and strong user recognition and, in our view, are poised to quickly generate traffic and revenue post-launch. Additionally, three SLG titles with different themes – including apocalypse, survival, and fantasy – are in the pipeline, further strengthening the overseas portfolio. In our view, the company has developed a mature methodology for SLG development, user acquisition, operations, and localized publishing, supporting high replication success rates for new titles. As subsequent releases roll out, a second growth curve is likely to emerge.
Earnings forecasts and valuation
We believe the new product cycle is underway, overseas SLG growth momentum is emerging, and AI empowerment could continue improving operational efficiency. We largely maintain our 2026/2027/2028 attributable NP forecast at RMB3,192/ 3,460/3,726mn. Considering the company's rich product pipeline, high overseas growth certainty, and potential AI-driven premium, we value the stock at 19.6x 2026E PE, above its peers' average of 14.7x (previous: 15.1x) on Wind consensus, for our target price of RMB28.25 (unchanged). Maintain BUY.
Risks: Performances of new titles missing our expectations, a rise in user acquisition costs, industry policy overhang.